Bridgewest WATER FOR INJECTION BP 100 mL injection solution vial Australia - English - Department of Health (Therapeutic Goods Administration)

bridgewest water for injection bp 100 ml injection solution vial

bridgewest perth pharma pty ltd - water for injections, quantity: 100 ml - injection, solution - excipient ingredients: - indications as at 11 august 2003: water for injections is used for the reconstitution and preparation of aqueous injections.

OXYCODONE-HAMELN oxycodone hydrochloride 50 mg/1 mL injection solution ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone-hameln oxycodone hydrochloride 50 mg/1 ml injection solution ampoule

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: citric acid monohydrate; hydrochloric acid; sodium citrate dihydrate; water for injections; sodium hydroxide; sodium chloride - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

OXYCODONE-HAMELN oxycodone hydrochloride 10 mg/1 mL injection solution ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone-hameln oxycodone hydrochloride 10 mg/1 ml injection solution ampoule

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium hydroxide; sodium chloride; hydrochloric acid; water for injections; citric acid monohydrate - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

OXYCODONE-HAMELN oxycodone hydrochloride 20 mg/2 mL injection solution ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone-hameln oxycodone hydrochloride 20 mg/2 ml injection solution ampoule

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; hydrochloric acid; sodium citrate dihydrate; water for injections; sodium hydroxide - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

HYDROCORTISONE INJECTION Kenya - English - Pharmacy and Poisons Board

hydrocortisone injection

surgilinks ltd. c/o kilitch drugs (india) ltd. p.o. box 14461 - 00800, nairobi - hydrocortisone injection 100mg - injection - injection - antibacterials for systemic use: amphenicols

ZEROVER INJECTION 150MG/ML Kenya - English - Pharmacy and Poisons Board

zerover injection 150mg/ml

surgilinks ltd. c/o kilitch drugs (india) ltd. p.o. box 14461 - 00800, nairobi - paracetamol injection 150mg/ml, 2ml - injection - injection - antibacterials for systemic use: amphenicols

SODIUM NITROPRUSSIDE BAXTER sodium nitroprusside 50 mg/2 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

sodium nitroprusside baxter sodium nitroprusside 50 mg/2 ml concentrated injection vial

baxter healthcare pty ltd - sodium nitroprusside, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - sodium nitroprusside baxter concentrated injection is indicated for:,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate.,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

Fresofol 1% MCT/LCT Propofol 1000mg/100mL Emulsion for Intravenous Injection/Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

fresofol 1% mct/lct propofol 1000mg/100ml emulsion for intravenous injection/infusion vial

fresenius kabi australia pty ltd - propofol, quantity: 10 g/l - injection, emulsion - excipient ingredients: medium chain triglycerides; water for injections; glycerol; sodium hydroxide; soya oil; egg lecithin; oleic acid - induction of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older.,maintenance of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older.,fresofol (1 percent) mct / lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,fresofol (1 percent) mct / lct has no analgesic properties. ,sedation during intensive care in adults,fresofol (1 percent) mct / lct may also be used in adults for sedation of ventilated patients receiving intensive care.,conscious sedation for surgical and diagnostic procedures in adults,fresofol (1 percent) mct / lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.

Fresofol 1% MCT/LCT Propofol 500mg/50mL Emulsion for Intravenous Injection/Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

fresofol 1% mct/lct propofol 500mg/50ml emulsion for intravenous injection/infusion vial

fresenius kabi australia pty ltd - propofol, quantity: 10 g/l - injection, emulsion - excipient ingredients: medium chain triglycerides; egg lecithin; sodium hydroxide; water for injections; oleic acid; glycerol; soya oil - induction of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older.,maintenance of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older.,fresofol (1 percent) mct / lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,fresofol (1 percent) mct / lct has no analgesic properties. ,sedation during intensive care in adults,fresofol (1 percent) mct / lct may also be used in adults for sedation of ventilated patients receiving intensive care.,conscious sedation for surgical and diagnostic procedures in adults,fresofol (1 percent) mct / lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.

Fresofol 1% MCT/LCT Propofol 200mg/20mL Emulsion for Intravenous Injection/Infusion ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

fresofol 1% mct/lct propofol 200mg/20ml emulsion for intravenous injection/infusion ampoule

fresenius kabi australia pty ltd - propofol, quantity: 10 g/l - injection, emulsion - excipient ingredients: medium chain triglycerides; sodium hydroxide; water for injections; glycerol; oleic acid; soya oil; egg lecithin - induction of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older.,maintenance of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older.,fresofol (1 percent) mct / lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,fresofol (1 percent) mct / lct has no analgesic properties. ,sedation during intensive care in adults,fresofol (1 percent) mct / lct may also be used in adults for sedation of ventilated patients receiving intensive care.,conscious sedation for surgical and diagnostic procedures in adults,fresofol (1 percent) mct / lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.